Hormone Therapy: Challenges for Treating Hearing Impairments

被引:0
作者
Joaquín Guerra
Jesús Devesa
机构
[1] Otolaryngology,
[2] Foltra Medical Center,undefined
[3] Foltra Medical Center,undefined
[4] Scientific Direction,undefined
[5] Foltra Medical Center,undefined
关键词
Hearing loss; Growth hormone; Hair cells; Auditory protection; Inner ear regeneration; Melatonin;
D O I
10.1007/s42399-019-00089-y
中图分类号
学科分类号
摘要
The purpose of this review is to summarize the advances and discoveries in the potential treatment with hormone analogs and some challenges still pending, beyond the classic treatment with corticosteroids. We conduct a review of the functions of hormones on hearing, in human and animal models, the presence of their most relevant receptors, and the desirable and undesirable effects for their therapeutic uses. Different hormones play a regulatory role in the development and maintenance of hearing. Hormone receptors in the ear have been identified over the years, which can be a support to use them as new therapeutic targets Moreover, their mediators, that include cells, neurotrophic factors, or other hormones, could be also useful for treating various hearing impairments The use of synthetic analogs could exert a therapeutic effect on hearing. Hormone therapy, in fact, can contribute positively to the treatment and prevention of various auditory pathologies, through the regeneration or protection. Considering that an optimal result has to be a garantee, it is a must to know their unwanted effects and contraindications. The use of hormones may protect, regenerate, and modulate multiple pathological conditions of the ear, but it would be necessary to standardize drug dosages, find alternative routes, and conduct prospective studies in humans.
引用
收藏
页码:603 / 615
页数:12
相关论文
共 491 条
[91]  
Price K(2014)Role of somatostatin receptor-2 in gentamicin-induced auditory hair cell loss in the mammalian inner ear PLoS One 9 308-undefined
[92]  
Zhu X(2018)The bone remodelling cycle Ann Clin Biochem 55 2033-undefined
[93]  
Guimaraes P(2002)Growth hormone and low dose estrogen in turner syndrome: results of a United States multi-center trial to near-final height J Clin Endocrinol Metab 87 23-undefined
[94]  
Vasilyeva O(2010)Growth hormone treatment does not affect incidences of middle ear disease or hearing loss in infants and toddlers with Turner syndrome Horm Res Paediatr 74 891-undefined
[95]  
Frisina R(1988)Stabilization of hearing loss in Paget’s disease with calcitonin and etidronate Arch Otolaryngol Head Neck Surg 114 267-undefined
[96]  
Horner K(2016)Treatment for progressive hearing loss due to Paget’s disease of bone – a case report and literature review J Int Adv Otol. 11 169-undefined
[97]  
Cazals Y(2003)Posible beneficio de la calcitonina en el tratamiento de la otosclerosis Acta Otorrinolaringol Esp 54 1295-undefined
[98]  
Guieu R(2008)Meniere’s attacks occur in the inner ear with excessive vasopressin type-2 receptors J Neuroendocrinol 20 901-undefined
[99]  
Lenoir M(2007)The relevance of an elevation in the plasma vasopressin levels to the pathogenesis of Meniere’s attack J Neuroendocrinol 19 613-undefined
[100]  
Sauze N(2011)Vasopressin in definite Meniere’s disease with positive electrocochleographic findings Acta Otolaryngol 131 161-undefined